Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Qdenga’s positive SEC opinion moves India close to its first widely available dengue vaccine, with import approval tied to a rapid post‑marketing s...
